SELLAS Life Sciences Group Inc
NASDAQ:SLS 4:00:00 PM EDT
Market Cap (Intraday) | 42.81M |
Current PE | N/A |
Forward PE | N/A |
2yr Forward PE | N/A |
10-Day MA | $1.52 |
50-Day MA | $1.55 |
200-Day MA | $1.93 |
SELLAS Life Sciences Group Inc Stock, NASDAQ:SLS
Times Square Tower, 7 Times Square, New York, New York 10036
United States of America
Phone: +1.646.200.5278
Number of Employees: 17
Description
SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S and nelipepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.